Pinnacle Associates’s Heron Therapeutics HRTX Stock Holding History

Pinnacle Associates’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-24,635	Closed	-$602K	–	723
2019 Q1	$602K	Sell	24,635 -4,345	-15%	-$114K	0.01%	501
2018 Q4	$752K	Sell	28,980 -960	-3%	-$26.4K	0.02%	445
2018 Q3	$948K	Sell	29,940 -15,975	-35%	-$595K	0.02%	424
2018 Q2	$1.78M	Buy	45,915 +2,255	+5%	+$71.8K	0.04%	324
2018 Q1	$1.21M	Buy	43,660 +32,560	+293%	+$739K	0.02%	372
2017 Q4	$201K	Buy	+11,100	New	+$181K	﹤0.01%	649

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Pinnacle Associates's HRTX Position: Q2 2019 in Review

Pinnacle Associates sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 24,635 shares — an estimated $602K sold.

Pinnacle Associates first reported a position in HRTX in Q4 2017 and held it in 6 quarters. The position peaked at $1.78M in Q2 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

Pinnacle Associates reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
Pinnacle Associates sold 24,635 Heron Therapeutics shares in Q2 2019, an estimated $602K.
Pinnacle Associates first reported a position in Heron Therapeutics in Q4 2017 and held it in 6 quarters.
Pinnacle Associates's Heron Therapeutics position peaked at $1.78M in Q2 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Pinnacle Associates's 13F filing for Q2 2019, filed 5 Aug 2019.